Eliem Therapeutics (ELYM)
(Delayed Data from NSDQ)
$6.99 USD
-0.37 (-5.03%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $6.96 -0.03 (-0.43%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.99 USD
-0.37 (-5.03%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $6.96 -0.03 (-0.43%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Eliem (ELYM) to Explore Strategic Options, Stock Rises 6%
by Zacks Equity Research
Eliem (ELYM) announces its decision to halt its Kv7 development program in its quest to explore strategic alternatives. The stock of the company rises 6% in response on Thursday.
Reata (RETA) Q1 Earnings Top, Omaveloxolone MAA Likely in Q4
by Zacks Equity Research
Reata (RETA) reports a narrower-than-expected loss for the first quarter of 2022 while revenues miss estimates.
Eliem Therapeutics, Inc. (ELYM) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Eliem Therapeutics, Inc. (ELYM) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.